In this prespecified exploratory biomarker analysis of the placebo-controlled CheckMate 274 trial, a composite model of adaptive immunity biomarkers and clinical parameters was identified and shown to predict benefit from nivolumab treatment in patients with muscle-invasive urothelial cancer.
- Matthew D. Galsky
- Dean F. Bajorin
- Andrea Necchi
